Archives

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
Has Treasury Wine Finally Found Its Floor After a Lost Decade?
Consumer Stocks

Has Treasury Wine Finally Found Its Floor After a Lost Decade?

Q: Why have Treasury Wine shares bounced recently? A: Demand returned to the stock at multi-year lows as the market judged pessimism excessive relative to the strength of the Penfolds brand. Q: What role does China play in the recovery case? A: The reopen

  • July 13, 2026 01:33 AM AEST
  • Sam
Little Green Pharma Leans on Europe as Cannabis Exports Grow
Cannabis Stocks

Little Green Pharma Leans on Europe as Cannabis Exports Grow

Little Green Pharma continues to build on its position as an early Australian exporter of medicinal cannabis to Europe, reporting meaningful revenue and positive adjusted earnings as the sector rewards distribution and export credentials.

  • July 13, 2026 01:31 AM AEST
  • Sam
Could BrainChip's Newest Chip Reset the Edge AI Race?
AI Stocks

Could BrainChip's Newest Chip Reset the Edge AI Race?

BrainChip Holdings approaches first production of its newest brain-inspired processor while surging global memory prices sharpen attention on Weebit Nano, Archer Materials and other early-stage semiconductor developers listed in Australia.

  • July 13, 2026 01:30 AM AEST
  • Sam
Is James Hardie the Quiet Value Story in Building?
Value Stocks

Is James Hardie the Quiet Value Story in Building?

James Hardie Industries trades below cash-flow based estimates of worth, with renovation and remodelling demand cushioning housing-cycle softness while its dominant North American fibre-cement franchise keeps generating durable cash flows.

  • July 13, 2026 01:28 AM AEST
  • Sam
Is the Data Centre Trade Back On for Australian Shares?
Technology Stocks

Is the Data Centre Trade Back On for Australian Shares?

NextDC anchors the digital infrastructure theme as technology sentiment recovers. Contracted capacity, power availability and funding costs will determine how the data centre build-out converts into durable returns.

  • July 13, 2026 01:27 AM AEST
  • Sam
Is Xero's (ASX:XRO) Chart Coiling for Its Next Big Move?
Technical Analysis

Is Xero's (ASX:XRO) Chart Coiling for Its Next Big Move?

Xero enters Friday coiled beneath tested resistance just as a strong Nasdaq session hands local technology charts a tailwind, with momentum, relative strength and sector breadth quietly improving.

  • July 13, 2026 01:25 AM AEST
  • Sam
Could Qoria (ASX:QOR) Be the ASX Safety-Tech Name Flying Under Radar?
Small Cap Stocks

Could Qoria (ASX:QOR) Be the ASX Safety-Tech Name Flying Under Radar?

Qoria is converting worldwide concern over children's online safety into an entrenched school-focused software business, using artificial intelligence to restrain costs while regulatory tailwinds keep expanding its addressable market.

  • July 13, 2026 01:21 AM AEST
  • Sam
Is the Temple & Webster (ASX:TPW) Pullback Cyclical or Something More?
Retail Stocks

Is the Temple & Webster (ASX:TPW) Pullback Cyclical or Something More?

Temple & Webster faces a proving season as shares drift and households spend selectively, with AI-driven efficiencies, commercial growth and online migration underpinning its longer structural story.

  • July 13, 2026 01:19 AM AEST
  • Sam
Can Arafura's Nolans (ASX:ARU) Turn Outback Ore Into Magnet Metal?
Rare Earth Minerals

Can Arafura's Nolans (ASX:ARU) Turn Outback Ore Into Magnet Metal?

Arafura Rare Earths finished site groundwork at Nolans, signed a binding Indian-linked offtake term sheet and pushed financing towards close, moving its integrated Territory rare earths build near construction.

  • July 13, 2026 01:17 AM AEST
  • Sam
Why Prescient Therapeutics (ASX:PTX) Tops Biotech Penny Watchlists
Penny Stocks

Why Prescient Therapeutics (ASX:PTX) Tops Biotech Penny Watchlists

and cell therapy work draw attention across ASX small caps. Post Summary: Prescient Therapeutics anchors biotech penny watchlists as its OmniCAR cell therapy platform draws steady attention, with trial milestones and cash runway shaping sentiment toward c

  • July 13, 2026 01:15 AM AEST
  • Sam
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.